New research tools targeting PCSK9 and LDLR

anti PCSK9 neutralizing ab - results

There is an increasing demand for new cholesterol-lowering therapies in addition to existing treatments (e.g. targeting statins). The pharmacological inhibition of PCSK9-mediated LDLR degradation is becoming very attractive for treating cholesterol-related diseases. But which reliable in vitro assays are available to effectively study “PCSK9-LDLR” interactions ?

PCSK9 function in LDLR degradation. Source tebu-bio.

PCSK9 function in LDLR degradation. Source: tebu-bio.

The Proprotein Convertase Subtilisin/Kexin type-9 (PCSK9) is a critical regulator of cholesterol metabolism.

PCSK9 interacts with the Low Density Lipoprotein Receptor (LDLR). The circulating PCSK9 endopetidase binds to the extracellular EGF-like domain of LDLR and targets it for lysosomal degradation.

Various research tools are already available to the research community for studying PCSK9, LDLR and their molecular interactions in vitro.

To begin with, there are many”conventional” popular monoclonal antibodies available, e.g. Anti Human PCSK9 polyclonal and Anti Human LDLR polyclonal  (100% guaranteed for WB applications) to monoclonal neutralizing Anti Human PCSK9 Antibodies compatible with WB and ELISA detection (biotin-labeled cat. nr 14971207 and 14971216 or cat. nr 14971216).

 

This slideshow requires JavaScript.

 

To further complement the”PCSK9-LDLR” research toolbox, BPS Bioscience have released recently new functional assays to better study the binding of these 2 targets and, the inhibition of this molecular interaction.

PCSK9 - LDLR BPS assay results. Source BPS tebu-bio.

“PCSK9 – LDLR” assay results: A) PCSK9 [B]-LDLR Interaction – B) Inhibition of PCSK9 [B]-LDLR by Anti-PCSK9.

Among these novelties, the PCSK9[Biotinylated]-LDLR Binding Assay Kit is of particular interest. The technology used in the assay brings unequaled and very high sensitivity, making this kit unique for screening and profiling purposes. Additionally, only a few experimental steps are required to perform the test made on a microtiter plate:

  1. LDLR ectodomain is coated on a 96-well plate
  2. PCSK9 is incubated with LDLR
  3. The plate is treated with streptavidin-HRP followed by addition of an HRP substrate to produce chemiluminescence

This new product-line also include kits and proteins compatible with in vitro binding assays:

If you’d like further information regarding these new BPS Bioscience reagents targeting PCSK9 and LDLR or concerning any other research tools in relation to cholesterol metabolism, feel free to leave your questions or comments below, or get in touch with your local tebu-bio office.

Subscribe to e-Newsletters on your favourite topicsInterested in learning more about tools like this?
Subscribe to thematic newsletters on your favourite research topics. 
Written by Ali El Baya, PhD
Ali el Bayâ is the Sales Manager at tebu-bio for the North of Europe.